In 1974 it was reported that three patients with acute pancreatitis had associated peritonitis and endotoxaemia, both of which disappeared when the disease resolved. 1 Cuevas et al showed that in experimental sterile peritonitis in rabbits there was release of endotoxin from the gut into the systemic circulation2 and it has been proposed that this was the source of endotoxin in patients with pancreatitis.1 3 There is evidence of increased complement catabolism in acute pancreatitis in man4 and studies of experimentally induced pancreatitis showed that complement activation may play a pathogenetic role, as the severity of the pancreatitis was reduced in complement-depleted animals.5 As endotoxin activates the complement system it is possible that endotoxaemia is responsible for at least some of the complement activation that occurs in this disease.
Patients with pancreatitis are prone to develop hypoxia, hypotension, renal failure, hypocalcaemia, and disseminated intravascular coagulation as complications.6 All of these changes can be produced experimentally by endotoxaemia.7 8 Patients who die of pancreatitis commonly have evidence of shock lung and, recently, complement activation has been associated with the development of this syndrome.9
The present study was designed to assess the incidence of endotoxaemia and complement activation in pancreatitis, to see if they were related, Received for publication 30 December 1981 and to correlate the presence of each with the development of complications.
Methods

PATIENTS
Patients with a diagnosis of acute pancreatitis substantiated by a serum amylase >1200 IU/1 were included in the study. Patients with postoperative or traumatic pancreatitis were excluded. The severity of the attack was assessed using Imrie's criteria.'0 Patients were considered to have severe acute pancreatitis if, within the first 48 hours of admission, three or more of the following nine prognostic factors were present: serum albumin <32 g/l (3.2 g/100 ml); serium calcium <2.0 mmol/l (8 mg/100 ml); white cell count >15x 109/l (15,000/mm3); transaminase enzymes >100 U/l: LDH >600 U/l; plasma glucose in excess of 10 mmol/l (180 mg/100 ml) (in the absence of known diabetes): blood urea >16 mmol/l (100 mg/100 ml) and not responding to intravenous therapy: age >55 years: Pa 02 <8 K Pa (<60 mmHg). Pa 02 was not always measured in patients who otherwise had a factor count of zero or one.
The patients were managed conservatively by nasogastric drainage and intravenous fluids with the exception of one patient who had a partial pancreatectomy 12 hours before death. Imrie Table 3 ) at some time during their illness, indicating increased C3 catabolism in acute pancreatitis. Samples taken during the first day after admission from patients with mild disease showed rises of mean C4 (mean±SEM=534±31 ,ug/ml), factor B (274±18 ,ug/ml), C3d (11.01±0.93 ,ug/ml) and CH50 (246±11.1 units) relative to normal controls (p<0-001 for each). Mean levels of C3 (1214±69 ,ug/ml) and AP-CH50 (270±18 units) did not differ from the norm. The findings on the The greatest degree of hypocomplementaemia was seen in the four patients who died (Table 2) . Within 24 hours of admission mean C3, CH50, and AP-CH50 were lower in non-survivors than survivors. Of the criteria used by Imrie to establish the severity of the attack of pancreatitis only the urea level was significantly different between the two groups at this time (p<0-01). Levels of C3, C4, and CH50 fell between the first and second sample in all the patients who died, whereas these values did not alter significantly in the survivors. At the time the second blood sample was taken all complement determinations were different between the two groups (Table 2), the best discriminating features being C3 and CH50 (Fig. 1 ).
COMPLEMENT ACTIVATION: ITS RELATIONSHIP TO EN DOTOXAEMIA
The mean levels of C3, factor B, CH50 and AP-CH50 were significantly reduced in the serum samples taken when patients had positive limulus lysate tests than when endotoxin was not detected in their blood (Table 3) . Levels of C3d were raised significantly in the endotoxin positive samples and mean C4 was the same in both groups. Similarly, patients with endotoxaemia were more likely to have abnormally low C3, AP-CH50 or CH50 than patients with no endotoxaemia (Table 1) .
SYSTEMIC COMPLICATIONS (Table 1) One patient who died was shocked, hypoxic, and developed acute renal failure. This patient did not have endotoxaemia. The three other patients who died did have endotoxaemia. Shock and renal failure were present in two of these patients one of whom also had necropsy evidence of disseminated intravascular coagulation. The third died of respiratory failure and also had disseminated intravascular coagulation at necropsy. Three survivors were shown to have complications, all of whom had endotoxaemia; two of these had evidence of intravascular coagulation (FDP level >40 gg/ml on day 1) and one of these patients was also hypoxic. The third survivor was hypoxic. When blood samples containing endotoxin were compared with blood samples in which endotoxin was not demonstrated the mean albumin corrected calcium level was the same in both groups. There was no significant correlation between any complement determinations and the development of specific complications.
Discussion
Half of the patients studied had endotoxaemia but only two of these patients had evidence of a Gram-negative bacterial source of endotoxin. Indwelling urinary catheters, associated with bacterial colonisation, have been reported to cause endotoxaemia15 but catheterisation did not appear to be related to its development in our patients. Thus it remains possible that the gut is the main source of endotoxin in pancreatitis.
One patient who died and showed evidence of respiratory and renal failure did not have endotoxaemia. Apart from this patient the six other patients either with respiratory or renal failure, or intravascular coagulation, all had endotoxaemia and in all a three-plus degree of endotoxaemia was detected. Liehr et al16 have reported an increased incidence of endotoxaemia in patients with complications of pancreatitis, and all nine of their patients who died had endotoxaemia. Hypocalcaemia, however, was not related to endotoxaemia in the present study.
Mean levels-of C4 and factor B were raised in patients with mild pancreatitis, and only the raised level of C3d in all these patients indicated that increased complement catabolism was present. Within 24 hours of admission the mean C3 level in patients with severe pancreatitis was reduced. In all four patients who died the level of C3 declined further during their illness. Levels of C3 rose during convalescence in the four patients with severe pancreatitis who survived. Thus, during an attack of severe pancreatitis, falling C3 levels are associated with a poor prognosis.
In any situation serum complement levels are determined by a balance between component synthesis and degradation. C3, C4, and factor B behave as acute phase reactants and tend to be raised in inflammatory diseases as a result of increased synthesis.17 The same factors are subject to increased consumption in acute pancreatitis as evidenced by raised C3d levels. Thus, in acute pancreatitis, synthesis and degradation are both increased and caution must be observed when interpreting results from a single blood sample, which may not show any abnormality other than an increased C3d level. Serial samples will give an indication of the balance that exists between synthesis and consumption. In patients with mild pancreatitis the balance is in favour of synthesis, resulting in increasing levels of C3, C4, and factor B during the acute phase of the illness. In fatal pancreatitis the balance is in favour of consumption.
In this study endotoxaemia appeared to be related to increased complement activation. Endotoxin can activate complement by at least three different mechanisms. First, the polysaccharide portion of the endotoxin molecule can activate the alternative pathway.18 Second, the same polysaccharide is a potent T-independent antigen and antibody binding with antigen will activate the classical pathway,, and third, the lipid A portion of the endotoxin combines directly with Cl to initiate classical pathway complement activation by an antibodyindependent mechanism.18.
In the bacteraemic phase preceding the development of septic shock in man there is evidence that complement activation is primarily by the alternative pathway.20 In our patients with endotoxaemia, activation by the alternative pathway was found more commonly (Table 1) , but there was evidence of activation by the classical pathway too, particularly in patients with severe disease.
The finding of increased C3d levels in patients who were not shown to have endotoxaemia suggests that agents other than endotoxin also activate the complement system in acute pancreatitis. In experimental pancreatitis in dogs, free trypsin was found in the pancreatic exudate in the early stages of the disease21 and trypsin is known to cleave C3, C4, and C5 to yield biologically active fragments. [22] [23] [24] However, attempts to demonstrate free proteolytic enzymes, unbound to plasma protease inhibitors, in either the circulation or in peritoneal exudates from patients with pancreatitis have failed. 4 25 Activation of the complement system within the pancreas by free trypsin remains a theoretical possibility. Although intrapancreatic C3 deposition has been reported in bile salt induced pancreatitis in rats, 5it
was not observed in choline deficiency pancreatitis in mice.
Most patients who die of pancreatitis do so within the first 10 days of the illness and they die of a shock syndrome characterised by cardiovascular and respiratory failure. 27 It is possible that the chemical peritonitis resulting from acute pancreatitis causes increased release of endotoxin fropm the gut lumen resulting in endotoxaemia and that endotoxaemia is at least partly responsible for the development of shock and other complications. If this is so, then treatment of the peritonitis may be of value. In animals, endotoxaemia caused by an ischaemic loop of bowel could be prevented by peritoneal lavage when lavage was started within 15 minutes of the onset of ischaemia. Endotoxaemia occurred in this model only when lavage was stopped.28 Therapeutic peritoneal lavage has been tried in the treatment of acute pancreatitis and has been shown to prevent deaths due to shock in the first 10 days.27 However, lavage does not appear to affect the inflammation in the pancreas. Other possible ways of preventing release of endotoxin from the gut include intralumenal cholestyramine which binds endotoxin,29 or gut sterilisation to eradicate the source of endotoxin.2 These therapeutic manoeuvres await clinical evaluation. 
